Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Sickle Cell Treatment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current market conditions, historical impact analysis (2021-2025), and forecast calculations (2026-2032), this report delivers a comprehensive evaluation of the global sickle cell treatment market—encompassing market size, share, demand dynamics, industry development status, and forward-looking projections essential for pharmaceutical executives, rare disease investors, hematology specialists, and healthcare policymakers.
The global market for sickle cell treatment was valued at an estimated US$242 million in 2024 and is projected to reach US$352 million by 2031, expanding at a steady CAGR of 5.6% over the forecast period. This growth trajectory reflects the convergence of novel disease-modifying therapies, groundbreaking gene editing approvals, expanded newborn screening programs, and increased access to comprehensive care in endemic regions.
By way of context, the global pharmaceutical market reached approximately US$1,475 billion in 2022, with a projected CAGR of 5% over the following six years. Within this market, biologics—including the gene therapies now entering the sickle cell space—accounted for approximately US$381 billion in 2022, while the chemical drug market grew from US$1,005 billion in 2018 to an estimated US$1,094 billion in 2022. Key market drivers include increasing healthcare demand, technological advancements, rising chronic disease prevalence, and expanded funding from both private and government organizations for pharmaceutical R&D. However, the industry continues to face challenges including stringent regulatory requirements, high R&D costs, and patent expirations, necessitating continuous innovation to maintain competitiveness and ensure patient access.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3670739/sickle-cell-treatment
Defining Sickle Cell Disease and Its Treatment Landscape
Sickle cell disease (SCD) is a genetic blood disorder caused by a mutation in the β-globin gene, resulting in the production of abnormal hemoglobin (HbS) that polymerizes under low-oxygen conditions. This polymerization causes red blood cells to assume a characteristic sickle shape, leading to hemolytic anemia, vaso-occlusive crises (VOCs)—episodes of severe pain caused by blocked blood vessels—and progressive end-organ damage affecting the spleen, lungs, kidneys, and brain.
The sickle cell treatment market encompasses three primary therapeutic modalities:
- Blood transfusion: Regular red blood cell exchange or simple transfusions to dilute HbS concentration, reducing VOC frequency and preventing stroke. Chronic transfusion programs require iron chelation therapy to manage iron overload.
- Bone marrow transplant (BMT) : Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only established curative option, with successful outcomes from HLA-matched sibling donors. However, transplant eligibility is limited by donor availability, transplant-related mortality risk, and the absence of matched donors for most patients.
- Pharmacotherapy: Disease-modifying drugs including hydroxyurea (the historical standard of care), L-glutamine (Endari), crizanlizumab (Adakveo), and voxelotor (Oxbryta). Emerging therapies include gene addition (lentiviral vector-mediated transfer of anti-sickling β-globin genes) and gene editing (CRISPR-Cas9-mediated reactivation of fetal hemoglobin).
Market Drivers: Gene Therapy Approvals, Expanded Access, and Novel Oral Agents
The sickle cell treatment market is propelled by several transformative developments.
First, gene therapy approvals represent a paradigm shift. In December 2023, the U.S. Food and Drug Administration (FDA) approved two milestone gene therapies: exagamglogene autotemcel (Casgevy, CRISPR Therapeutics/Vertex Pharmaceuticals), the first CRISPR-based therapy approved for any indication, and lovotibeglogene autotemcel (Lyfgenia, bluebird bio). These one-time curative treatments involve autologous stem cell collection, ex vivo genetic modification, and reinfusion following myeloablative conditioning. Regulatory approvals in Europe and other jurisdictions are expanding patient access, though treatment costs (exceeding US$2 million per patient) and specialized transplant infrastructure requirements remain significant barriers.
Second, expanded newborn screening programs in sub-Saharan Africa—where approximately 75% of the global SCD burden resides—are driving earlier diagnosis and treatment initiation. Countries including Nigeria, the Democratic Republic of Congo, India, and Brazil have implemented or expanded screening programs, creating demand for affordable hydroxyurea formulations and comprehensive care models. The World Health Organization (WHO) has designated SCD a global health priority, with resolutions urging member states to develop integrated SCD control programs.
Third, novel oral agents continue to enter the pipeline. Recent approvals and late-stage candidates target distinct pathogenic mechanisms: pyruvate kinase activators (mitapivat), HbS polymerization inhibitors, and p-selectin antagonists. These oral therapies offer advantages in convenience and accessibility compared to intravenous biologics or transplant-based curative approaches.
Treatment Modality Segmentation: Pharmacotherapy Leads, Transplants Grow
The sickle cell treatment market is segmented by treatment type into blood transfusion, bone marrow transplant, and pharmacotherapy.
Pharmacotherapy represents the largest segment, accounting for approximately 62% of global market revenue in 2024. Hydroxyurea remains the most widely used disease-modifying agent, with generic availability enabling broad access in low-resource settings. Novel agents including voxelotor (HbS polymerization inhibitor) and crizanlizumab (p-selectin inhibitor) command premium pricing but face access limitations due to cost and reimbursement constraints.
Blood transfusion represents the second-largest segment, with chronic transfusion programs essential for stroke prevention in high-risk pediatric patients and for management of acute complications including acute chest syndrome and multi-organ failure. The segment benefits from established infrastructure but faces challenges including iron overload management, alloimmunization risk, and transfusion-transmitted infection concerns in endemic regions.
Bone marrow transplant represents the smallest but fastest-growing segment, with a projected CAGR of 8.2% through 2031. Growth is driven by reduced-intensity conditioning protocols that expand eligibility, increased availability of alternative donors (haploidentical, unrelated, cord blood), and the curative potential of gene therapy approaches that fall within the transplant procedural category.
Application Segmentation: Hospitals Dominate, Clinics Expand
The sickle cell treatment market is segmented by care setting into hospitals, clinics, and other settings.
Hospitals represent the largest application segment, accounting for approximately 78% of global market revenue in 2024. Hospital-based care is essential for acute VOC management (requiring parenteral opioids and hydration), chronic transfusion programs, bone marrow transplantation, and management of SCD complications including stroke, acute chest syndrome, and priapism.
Clinics (comprehensive SCD centers, hematology outpatient clinics) represent the fastest-growing application segment, with a projected CAGR of 6.7% through 2031. Expanded access to disease-modifying pharmacotherapy, routine preventive care, and telemedicine follow-up is shifting care to outpatient settings, reducing hospitalization rates and healthcare costs while improving patient quality of life.
Competitive Landscape
The sickle cell treatment market features a competitive landscape with established pharmaceutical companies, gene therapy developers, and specialty rare disease firms. Key players profiled in the report include Novartis AG, Global Blood Therapeutics Inc. (acquired by Pfizer), EMI Holding, Inc. , Addmedica Inc. , Medunik USA Inc. , Bristol Myers Squibb Co. , Baxter Inc. , Bluebird Biotechnology, Pfizer Inc. , Eli-Lilly and Co. , Glycomimetics Inc. , F. Hoffmann-La Roche, and CRISPR Therapeutics.
The competitive landscape is characterized by:
- Gene therapy entrants: CRISPR Therapeutics and bluebird bio have established curative platforms, with additional developers in clinical stages
- Oral agent development: Late-stage candidates targeting HbS polymerization, pyruvate kinase activation, and other mechanisms
- Global access partnerships: Collaborations between pharmaceutical companies, governments, and non-profits to improve access in low- and middle-income countries
- Combination therapy research: Investigations of novel agents added to hydroxyurea backbone for enhanced efficacy
Market Challenges: Access, Affordability, and Infrastructure
The sickle cell treatment market faces significant challenges. Access and affordability remain the most critical barriers, particularly for gene therapies with multimillion-dollar price tags and for novel oral agents requiring specialty pharmacy distribution. Most affected individuals reside in low-resource settings where basic hydroxyurea access remains inconsistent.
Specialized infrastructure for transplantation and gene therapy—including apheresis capabilities, cleanroom facilities, and transplant expertise—is concentrated in high-income countries, limiting curative treatment access for the majority of the global SCD population.
Clinical trial diversity remains inadequate, with SCD therapies historically studied predominantly in North American and European populations despite the disease’s highest prevalence in sub-Saharan Africa and India. Regulatory agencies are increasingly requiring global trial programs that include endemic regions.
Regional Dynamics: North America Leads, Africa Emerges
North America remains the largest regional market, driven by gene therapy approvals, specialty pharmacy distribution, and comprehensive SCD center infrastructure. Europe follows, with the United Kingdom, France, and Germany leading access to novel therapies through national health systems. Africa represents the fastest-growing region for basic interventions (hydroxyurea, newborn screening, VOC management) through international partnerships and government initiatives, though access to advanced therapies remains extremely limited.
Conclusion
The sickle cell treatment market is positioned for sustained growth through 2031, driven by gene therapy approvals, expanded pharmacotherapy options, and increased global focus on SCD as a health priority. Success in this market requires pharmaceutical companies to balance curative therapy development with affordable access strategies, invest in clinical trial diversity, and partner with governments and non-profits to reach affected populations in endemic regions. The report *“Sickle Cell Treatment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”* provides the granular segmentation analysis, competitive intelligence, and forward-looking forecasts essential for stakeholders navigating this transformative rare disease therapeutic area.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
